Morgan Stanley Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri maintains an Equal-Weight rating on Integra Lifesciences (NASDAQ:IART) and lowers the price target from $59 to $43.
May 31, 2023 | 11:36 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley maintains an Equal-Weight rating on Integra Lifesciences and lowers the price target from $59 to $43.
The news directly mentions Integra Lifesciences (IART) and the lowered price target by Morgan Stanley. This may cause some investors to reevaluate their positions, but the Equal-Weight rating suggests that the stock is still fairly valued. The impact on the stock price is expected to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100